Wall Street brokerages forecast that Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT – Get Rating) will report sales of $5.37 million for the current quarter, according to Zacks. Three analysts have provided estimates for Opiant Pharmaceuticals’ earnings, with the highest sales estimate coming in at $9.72 million and the lowest estimate coming in at $1.90 million. Opiant Pharmaceuticals posted sales of $11.26 million in the same quarter last year, which suggests a negative year-over-year growth rate of 52.3%. The company is expected to issue its next earnings results on Monday, January 1st.
According to Zacks, analysts expect that Opiant Pharmaceuticals will report full-year sales of $21.05 million for the current fiscal year, with estimates ranging from $10.00 million to $34.86 million. For the next fiscal year, analysts anticipate that the company will report sales of $60.00 million, with estimates ranging from $55.00 million to $65.00 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Opiant Pharmaceuticals.
Opiant Pharmaceuticals (NASDAQ:OPNT – Get Rating) last released its quarterly earnings data on Tuesday, May 10th. The technology company reported ($2.43) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($1.68). The company had revenue of $4.47 million during the quarter, compared to analyst estimates of $7.13 million. Opiant Pharmaceuticals had a negative net margin of 13.70% and a negative return on equity of 15.28%. During the same quarter in the prior year, the company posted ($0.66) EPS.
Opiant Pharmaceuticals stock opened at $14.98 on Thursday. The firm has a market cap of $76.10 million, a PE ratio of -10.33 and a beta of 0.65. The company has a debt-to-equity ratio of 0.35, a quick ratio of 8.72 and a current ratio of 8.72. The firm’s 50 day moving average price is $20.51 and its two-hundred day moving average price is $25.68. Opiant Pharmaceuticals has a twelve month low of $7.34 and a twelve month high of $37.71.
Hedge funds have recently bought and sold shares of the business. Dorsey Wright & Associates bought a new stake in Opiant Pharmaceuticals in the fourth quarter worth approximately $72,000. Morgan Stanley grew its position in Opiant Pharmaceuticals by 11.8% in the first quarter. Morgan Stanley now owns 9,476 shares of the technology company’s stock worth $101,000 after acquiring an additional 1,000 shares in the last quarter. Hillsdale Investment Management Inc. bought a new stake in Opiant Pharmaceuticals in the fourth quarter worth approximately $108,000. JPMorgan Chase & Co. boosted its holdings in shares of Opiant Pharmaceuticals by 10.7% during the 1st quarter. JPMorgan Chase & Co. now owns 7,466 shares of the technology company’s stock worth $160,000 after buying an additional 723 shares during the period. Finally, Advisor Group Holdings Inc. boosted its holdings in shares of Opiant Pharmaceuticals by 102.4% during the 3rd quarter. Advisor Group Holdings Inc. now owns 6,325 shares of the technology company’s stock worth $163,000 after buying an additional 3,200 shares during the period. 27.93% of the stock is owned by institutional investors.
Opiant Pharmaceuticals Company Profile (Get Rating)
Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders.
- Get a free copy of the StockNews.com research report on Opiant Pharmaceuticals (OPNT)
- MarketBeat Podcast: Options Trading As Easy As Trading Stocks
- The TJX Companies: It’s Not All Doom And Gloom In Retail
- Simply Good Foods Stock is Simply Looking Good Down Here
- Shoe Carnival’s Q1 Results Are No Joke, Shares Fall 15%
- Dynatrace: Fundamentals are Positive While Being Punished
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.